Generally considered safe, but caution advised for those with autoimmune conditions. Not recommended for long-term use (more than 8 weeks continuously).

Safety note^{[15, 16, 17]}Caution

Duke (2002) rates echinacea as +++ — among the most thoroughly documented herbal immunostimulants. It notes experimental and clinical evidence for immunostimulant, antiviral, and anti-inflammatory activities. Multiple species have been studied (E. purpurea, E. angustifolia, E. pallida), and Duke emphasizes that species identification in commercial products is often unreliable. Commission E approves E. purpurea for supporting immune function during colds and flu. Dose: 900 mg standardized extract daily in acute use; use should be limited to 8 weeks continuous. Contraindicated in autoimmune diseases (MS, lupus, HIV/AIDS), tuberculosis, and with immunosuppressive drugs (cyclosporine) (Duke, 2002).

References

REF-0797, REF-0798, REF-0799, REF-2011, REF-2012, REF-2013, REF-2014, REF-2015, REF-2016, REF-2017, REF-2018, REF-2019, REF-2020, REF-2021

References & Sources

Karsch-Völk, M., Barrett, B., Kiefer, D., Bauer, R. et al (2014) 'Echinacea for preventing and treating the common cold', Cochrane Database of Systematic Reviews, 2(2), pp. CD000530. doi:10.1002/14651858.CD000530.pub3 Meta-analysis / review
https://doi.org/10.1002/14651858.CD000530.pub3
Kamin, W., Seifert, G., Zwiauer, K., Bonhoeffer, J. et al (2025) 'Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review', Frontiers in Pediatrics, 13, pp. 1423250. doi:10.3389/fped.2025.1423250 Meta-analysis / review
https://doi.org/10.3389/fped.2025.1423250
Fashner, J., Ericson, K. and Werner, S (2012) 'Treatment of the common cold in children and adults', American Family Physician, 86(2), pp. 153-159. Available at: https://pubmed.ncbi.nlm.nih.gov/22962927/ Traditional / reference
https://pubmed.ncbi.nlm.nih.gov/22962927/
Manayi, A., Vazirian, M. and Saeidnia, S (2015) 'Echinacea purpurea: Pharmacology, phytochemistry and analysis methods', Pharmacognosy Reviews, 9(17), pp. 63-72. doi:10.4103/0973-7847.156353 Meta-analysis / review
https://doi.org/10.4103/0973-7847.156353
Burlou-Nagy, C., Banica, F., Jurca, T., Vicas, L.G., Marian, E., Muresan, M.E., Bacskay, I., Kiss, R., Feher, P. and Pallag, A (2022) 'Echinacea purpurea (L.) Moench: Biological and Pharmacological Properties. A Review', Plants, 11(9), pp. 1244. doi:10.3390/plants11091244 Meta-analysis / review
https://doi.org/10.3390/plants11091244
Hall, H., Fahlman, M.M. and Engels, H.J (2007) 'Echinacea purpurea and mucosal immunity', International Journal of Sports Medicine, 28(9), pp. 792-797. doi:10.1055/s-2007-964895 Randomized trial
https://doi.org/10.1055/s-2007-964895
Ross, S.M (2016) 'Echinacea purpurea: A Proprietary Extract of Echinacea purpurea Is Shown to be Safe and Effective in the Prevention of the Common Cold', Holistic Nursing Practice, 30(1), pp. 54-57. doi:10.1097/HNP.0000000000000130 Meta-analysis / review
https://doi.org/10.1097/HNP.0000000000000130
Hudson, J.B (2011) 'Applications of the phytomedicine Echinacea purpurea (Purple Coneflower) in infectious diseases', Journal of Biomedicine & Biotechnology, 2012, pp. 769896. doi:10.1155/2012/769896 Meta-analysis / review
https://doi.org/10.1155/2012/769896
Mishima, S., Saito, K., Maruyama, H., Inoue, M., Yamashita, T., Ishida, T. and Gu, Y (2004) 'Antioxidant and immuno-enhancing effects of Echinacea purpurea', Biological & Pharmaceutical Bulletin, 27(7), pp. 1004-1009. doi:10.1248/bpb.27.1004 Preclinical
https://doi.org/10.1248/bpb.27.1004
Saunders, P.R., Smith, F. and Schusky, R.W (2007) 'Echinacea purpurea L. in children: safety, tolerability, compliance, and clinical effectiveness in upper respiratory tract infections', Canadian Journal of Physiology and Pharmacology, 85(11), pp. 1195-1199. doi:10.1139/Y07-103 Clinical study
https://doi.org/10.1139/Y07-103
Micheli, L., Maggini, V., Ciampi, C., Gallo, E., Bogani, P., Fani, R., Pistelli, L., Ghelardini, C., Di Cesare Mannelli, L., De Leo, M. and Firenzuoli, F (2022) 'Echinacea purpurea against neuropathic pain: Alkamides versus polyphenols efficacy', Phytotherapy Research, 37(5), pp. 1911-1923. doi:10.1002/ptr.7709 Preclinical
https://doi.org/10.1002/ptr.7709
Gholami, M., Amri, J., Pazhoohan, S. and Sadegh, M (2021) 'Anticonvulsive and anti-epileptogenesis effects of Echinacea purpurea root extract, an involvement of CB2 receptor', Journal of Complementary & Integrative Medicine, 19(4), pp. 879-886. doi:10.1515/jcim-2020-0219 Preclinical
https://doi.org/10.1515/jcim-2020-0219
Awortwe, C., Bruckmueller, H., Kaehler, M. and Cascorbi, I (2021) 'Interaction of Phytocompounds of Echinacea purpurea with ABCB1 and ABCG2 Efflux Transporters', Molecular Pharmaceutics, 18(4), pp. 1622-1633. doi:10.1021/acs.molpharmaceut.0c01075 Preclinical
https://doi.org/10.1021/acs.molpharmaceut.0c01075
Perry, N.B., van Klink, J.W., Burgess, E.J. and Parmenter, G.A (1997) 'Alkamide levels in Echinacea purpurea: a rapid analytical method revealing differences among roots, rhizomes, stems, leaves and flowers', Planta Medica, 63(1), pp. 58-62. doi:10.1055/s-2006-957605 Preclinical
https://doi.org/10.1055/s-2006-957605
Linde, K., Barrett, B., Wölkart, K., Bauer, R. and Melchart, D (2006) 'Echinacea for preventing and treating the common cold'. Traditional / reference
Find this source
Sharma, M., Schoop, R., Suter, A. and Schoop, W (2010) 'The possibility of prophylactic treatment of streptococcal pharyngotonsillitis with a standardized Echinacea preparation', 29(8), pp. 1025--1035. Traditional / reference
Find this source
World Health Organization (1999) 'WHO Monographs on Selected Medicinal Plants'. Traditional / reference
Find this source

Generated June 22, 2026 from omniasana.bio